On August 21, CANSINOBIO fell 7.99% in regular trading, trading at HK$29.94/share, with turnover of HK$305 million. The stock had surged approximately 48.76% in the prior session, closing at HK$34.72.

The decline follows a sharp rally on August 20 triggered by Moderna and Merck's announcement that their co-developed personalized mRNA cancer vaccine achieved positive results in the first-ever Phase 3 clinical trial for mRNA tumor vaccines. Moderna's stock surged over 170% on the news. CANSINOBIO benefited as it possesses a proprietary ISL-3C-LNP delivery system specifically designed for therapeutic cancer vaccines, with multiple mRNA tumor vaccine pipelines under development. Analysts from CLSA noted that the company's development approach and antigen design are broadly similar to Moderna's, with its differentiated three-component lipid nanoparticle system potentially supporting stronger cellular immune responses.

Separately, the company announced on August 20 that its tetanus vaccine received NDA approval from China's NMPA, further expanding its commercialized product portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)